Metformin's effect on Growth Hormone-induced IGF-1 in SGA children studied

Small for Gestational Age (SGA) children often experience short stature and may not achieve their full growth potential. While Growth Hormone (GH) therapy is a standard treatment, some children exhibit suboptimal responses, potentially due to underlying insulin resistance or impaired IGF-1 generation. Enhancing insulin sensitivity could theoretically improve the downstream effects of GH, leading to better IGF-1 production and, consequently, improved growth outcomes. This study explores this therapeutic gap.

This multicenter, randomized, open-label, dose-response trial enrolled 96 GH-treatment-naïve, non-GH-deficient, prepubertal short children born SGA. Participants received Growth Hormone (GH) therapy, with an investigational arm also receiving Metformin treatment. The study aimed to determine if Metformin improved GH response, specifically by increasing blood Insulin-like growth factor -1 (IGF-1) concentrations and promoting growth. The main phase spanned 52 weeks, followed by an ongoing safety extension.

The provided abstract outlines the study's design and objectives but does not present any specific results or findings. The trial is designed to assess the impact of Metformin on IGF-1 response to Growth Hormone (GH) in SGA children, with data on growth and IGF-1 concentrations expected upon completion. No statistical outcomes, percentages, or p-values are available from this preliminary information.